Southport Capital Management’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Southport Capital Management’s Portfolio LABD Stock Details LABD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.46M	Buy	+4,147	New	+$1.63M	0.53%	51

Other funds holding LABD

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Southport Capital Management's LABD Position: Q1 2022 in Review

Southport Capital Management opened a new position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2022: 4,147 shares worth $1.46M. The stake represents 0.53% of the portfolio and ranks #51 among its holdings.

17 funds tracked by Wall St. Rank hold LABD as of Q1 2022.

Southport Capital Management held 4,147 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $1.46M as of Q1 2022.
Direxion Daily S&P Biotech Bear 3X ETF was a new Southport Capital Management position in Q1 2022.
Direxion Daily S&P Biotech Bear 3X ETF made up 0.53% of Southport Capital Management's portfolio in Q1 2022, its #51 holding.
17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2022.

Based on Southport Capital Management's 13F filing for Q1 2022, filed 25 Apr 2022.